RVPH: Reviva Pharmaceuticals Holdings, Inc. Total Debt to Capital

The historical price chart for Reviva Pharmaceuticals (RVPH) on GURU.Markets demonstrates a total debt-to-equity ratio of 0.05. Reviva Pharmaceuticals develops medications for bipolar disorder and schizophrenia, aiming to minimize negative therapy side effects for CNS patients. The business's environmental profile is limited to the safe disposal of laboratory waste. Experienced executives are focused on the final testing phases and engagement with regulatory authorities.

The Debt/Equity ratio measures the proportion of borrowed funds relative to equity, determining the company's degree of financial autonomy and level of credit risk. For Reviva Pharmaceuticals (RVPH), which finances the development of neuroleptics through investments, changes in the ratio of total debt to equity reflect balance sheet resilience during periods of zero operating revenue and the quality of asset management.